

14. (Amended) The antibody of claim 13, wherein said polypeptide comprises at least 4 contiguous amino acids of the amino acid sequence shown in Figure 3.
15. (Amended) A hybridoma which produces an antibody having specific binding affinity to a BDP1 polypeptide.
16. (Amended) The hybridoma of claim 15, wherein said polypeptide comprises at least 25 contiguous amino acids present of the amino acid sequence shown in Figure 3.
21. (Amended) A method of detecting a compound capable of binding to a BDP1 polypeptide, comprising the steps of incubating said compound with said polypeptide and detecting the presence of said compound bound to said polypeptide.
22. (Amended) A method of identifying a compound capable of activating or inhibiting BDP1 protein phosphorylation activity wherein said method comprises the following steps:
adding a compound to a mixture containing a BDP1 polypeptide and a substrate for said protein; and
detecting a change in phosphorylation of said substrate.
23. (Amended) A method of identifying compounds useful for diagnosis or treatment of an abnormal condition in an organism, wherein said abnormal condition is associated with an aberration in a signal transduction pathway characterized by an interaction between a polypeptide and a natural binding partner, wherein said polypeptide is a BDP1 polypeptide, comprising the following steps:
adding a compound to cells; and
detecting whether the compound promotes or disrupts said interaction between the polypeptide and a natural binding partner.
24. (Amended) A method for diagnosis or a disease or condition characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway includes